home / stock / allo / allo quote
Last: | $3.07 |
---|---|
Change Percent: | -3.7% |
Open: | $3.08 |
Close: | $3.07 |
High: | $3.24 |
Low: | $3.02 |
Volume: | 1,332,127 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.07 | $3.08 | $3.07 | $3.24 | $3.02 | 1,332,127 | 05-03-2024 |
$2.97 | $3.07 | $2.97 | $3.09 | $2.92 | 1,400,492 | 05-02-2024 |
$2.92 | $2.78 | $2.92 | $3.029 | $2.74 | 2,585,417 | 05-01-2024 |
$2.76 | $2.8 | $2.76 | $2.91 | $2.7 | 2,151,154 | 04-30-2024 |
$2.84 | $2.94 | $2.84 | $3.1 | $2.785 | 3,060,517 | 04-29-2024 |
$2.89 | $2.87 | $2.89 | $2.93 | $2.75 | 2,452,436 | 04-26-2024 |
$2.855 | $2.99 | $2.855 | $2.99 | $2.84 | 2,772,870 | 04-25-2024 |
$3.04 | $3.37 | $3.04 | $3.42 | $3.03 | 2,107,578 | 04-24-2024 |
$3.37 | $3.41 | $3.37 | $3.53 | $3.36 | 1,606,756 | 04-23-2024 |
$3.4 | $3.49 | $3.4 | $3.63 | $3.38 | 1,789,993 | 04-22-2024 |
$3.47 | $3.45 | $3.47 | $3.555 | $3.38 | 2,013,218 | 04-19-2024 |
$3.46 | $3.52 | $3.46 | $3.56 | $3.45 | 1,245,819 | 04-18-2024 |
$3.51 | $3.57 | $3.51 | $3.58 | $3.455 | 2,507,828 | 04-17-2024 |
$3.5 | $3.5 | $3.5 | $3.555 | $3.395 | 1,388,064 | 04-16-2024 |
$3.55 | $3.86 | $3.55 | $3.88 | $3.535 | 1,592,742 | 04-15-2024 |
$3.8 | $3.98 | $3.8 | $4.0062 | $3.74 | 2,882,301 | 04-12-2024 |
$3.99 | $4.14 | $3.99 | $4.21 | $3.99 | 2,153,258 | 04-11-2024 |
$4.07 | $3.91 | $4.07 | $4.25 | $3.87 | 2,326,913 | 04-10-2024 |
$4.11 | $3.99 | $4.11 | $4.11 | $3.93 | 1,368,742 | 04-09-2024 |
$3.98 | $3.96 | $3.98 | $4.04 | $3.895 | 1,129,476 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger ® Technology to Optimize CAR T Cell Expansion and Pe...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...